{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:48Z","timestamp":1790724528259,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Cancer Foundation Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003127","name":"Finnish Red Cross Blood Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003127","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane and Aatos Erkko Fundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:07:13Z","timestamp":1778760433000},"page":"4670-4686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors"],"prefix":"10.1016","volume":"34","author":[{"given":"Elise","family":"Jirovec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriina J.","family":"Jalkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C.A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.A.","family":"Clubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomo","family":"Alanko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santeri A.","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Gr\u00f6nberg-V\u00e4h\u00e4-Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirte","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniina","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Kononen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorma","family":"Sormunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Kemppainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Hellesuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced Non\u2012Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"ONCOLYTIC VIROTHERAPY","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12935-022-02585-z","article-title":"Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction","volume":"221","author":"Mardi","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ymthe.2026.05.007_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001486","article-title":"Clinical landscape of oncolytic virus research in 2020","volume":"8","author":"Macedo","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"203","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.007_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/hum.1997.8.1-37","article-title":"Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration","volume":"8","author":"Worgall","year":"1997","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017076","article-title":"Real-Time Dynamic Imaging of Virus Distribution In Vivo","volume":"6","author":"Hofherr","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1478-3231.2006.01342.x","article-title":"Role of Kupffer cells in host defense and liver disease","volume":"26","author":"Bilzer","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.ymthe.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ymthe.2005.08.007","article-title":"Rapid Kupffer cell death after intravenous injection of adenovirus vectors","volume":"13","author":"Manickan","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1525-0016(02)00017-5","article-title":"Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors","volume":"7","author":"Schiedner","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymthe.2005.06.477","article-title":"Lipid Emulsions Potently Increase Transgene Expression in Hepatocytes after Adenoviral Transfer","volume":"13","author":"Snoeys","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0131242","article-title":"Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-Cell Therapy in solid tumors","volume":"10","author":"T\u00e4htinen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ymthe.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/gt.2008.56","article-title":"Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies","volume":"15","author":"S\u00e4rkioja","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.it.2013.04.005","article-title":"The innate immune response during liver inflammation and metabolic disease","volume":"34","author":"Bieghs","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dsx.2020.11.023","article-title":"Performance of serum CD163 as a marker of fibrosis in patients with NAFLD","volume":"15","author":"Ragab","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.ymthe.2026.05.007_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.007_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12967","article-title":"Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms","volume":"93","author":"Jafarzadeh","year":"2021","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ymthe.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.4049\/jimmunol.1900961","article-title":"CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the Blood","volume":"203","author":"Zhao","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.4049\/jimmunol.170.12.5999","article-title":"IL-1\u03b2 Scavenging by the Type II IL-1 Decoy Receptor in Human Neutrophils","volume":"170","author":"Bourke","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1073\/pnas.1911678117","article-title":"Trans-endocytosis of intact IL-15R\u03b1\u2013IL-15 complex from presenting cells into NK cells favors signaling for proliferation","volume":"117","author":"Anton","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2026.05.007_bib30","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.05.007_bib31","first-page":"442","article-title":"Ad5\/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes","volume":"285","author":"Zafar","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1002\/1873-3468.13649","article-title":"Interaction of adenovirus with antibodies, complement, and coagulation factors","volume":"593","author":"Allen","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2026.05.007_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.007_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071697","article-title":"In Vivo Tracking for Oncolytic Adenovirus Interactions with Liver Cells","volume":"10","author":"Naumenko","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2026.05.007_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/mthe.2000.0227","article-title":"Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver","volume":"3","author":"Tao","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s42003-022-04254-3","article-title":"Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes","volume":"5","author":"Naumenko","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mt.2011.230","article-title":"Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer","volume":"20","author":"Koski","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib38","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[18F]-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Response Evaluation of Oncolytic Adenovirus Treatments of Patients with Advanced Cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.05.007_bib40","doi-asserted-by":"crossref","first-page":"e14581","DOI":"10.1200\/JCO.2024.42.16_suppl.e14581","article-title":"Intravenous infusion (IV) or intracavitary perfusion (IP) of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody: Analyses of two phase 1 studies","volume":"42","author":"Niu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib41","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109168","article-title":"The impact of infection and inflammation in oncologic 18F-FDG PET\/CT imaging","volume":"117","author":"Rahman","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ymthe.2026.05.007_bib43","article-title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","volume":"24","author":"Monberg","year":"2024","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.ymthe.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/10430340260185139","article-title":"Serum and Ascites Neutralizing Antibodies in Ovarian Cancer Patients Treated with Intraperitoneal Adenoviral Gene Therapy","volume":"13","author":"Hemminki","year":"2002","journal-title":"Hum. Gene Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:27:36Z","timestamp":1786073256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626003941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626003941"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.007","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}